137 related articles for article (PubMed ID: 19005267)
41. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.
Wyl Vv; Gianella S; Fischer M; Niederoest B; Kuster H; Battegay M; Bernasconi E; Cavassini M; Rauch A; Hirschel B; Vernazza P; Weber R; Joos B; Günthard HF;
PLoS One; 2011; 6(11):e27463. PubMed ID: 22102898
[TBL] [Abstract][Full Text] [Related]
42. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.
Zolopa A; Andersen J; Powderly W; Sanchez A; Sanne I; Suckow C; Hogg E; Komarow L
PLoS One; 2009; 4(5):e5575. PubMed ID: 19440326
[TBL] [Abstract][Full Text] [Related]
43. Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection.
Steingrover R; Garcia EF; van Valkengoed IG; Bekker V; Bezemer D; Kroon FP; Dekker L; Prins M; de Wolf F; Lange JM; Prins JM
AIDS Res Hum Retroviruses; 2010 Apr; 26(4):379-87. PubMed ID: 20377419
[TBL] [Abstract][Full Text] [Related]
44. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines.
Lodi S; Phillips A; Touloumi G; Geskus R; Meyer L; Thiébaut R; Pantazis N; Amo JD; Johnson AM; Babiker A; Porter K;
Clin Infect Dis; 2011 Oct; 53(8):817-25. PubMed ID: 21921225
[TBL] [Abstract][Full Text] [Related]
45. Safety of monitoring antiretroviral therapy response in HIV-1 infection using CD4+ T cell count at long-term intervals.
Vogler IH; Alfieri DF; Gianjacomo HDB; Almeida ERD; Reiche EMV
Cad Saude Publica; 2018 Oct; 34(10):e00009618. PubMed ID: 30365742
[TBL] [Abstract][Full Text] [Related]
46. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.
Babiker AG; Emery S; Fätkenheuer G; Gordin FM; Grund B; Lundgren JD; Neaton JD; Pett SL; Phillips A; Touloumi G; Vjechaj MJ;
Clin Trials; 2013; 10(1 Suppl):S5-S36. PubMed ID: 22547421
[TBL] [Abstract][Full Text] [Related]
47. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Panel de expertos de GESIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
[TBL] [Abstract][Full Text] [Related]
48. Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure.
Lodi S; Phillips A; Fidler S; Hawkins D; Gilson R; McLean K; Fisher M; Post F; Johnson AM; Walker-Nthenda L; Dunn D; Porter K;
PLoS One; 2013; 8(9):e75608. PubMed ID: 24086588
[TBL] [Abstract][Full Text] [Related]
49. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.
Hocqueloux L; Avettand-Fènoël V; Jacquot S; Prazuck T; Legac E; Mélard A; Niang M; Mille C; Le Moal G; Viard JP; Rouzioux C;
J Antimicrob Chemother; 2013 May; 68(5):1169-78. PubMed ID: 23335199
[TBL] [Abstract][Full Text] [Related]
50. Long-term Therapeutic Impact of the Timing of Antiretroviral Therapy in Patients Diagnosed With Primary Human Immunodeficiency Virus Type 1 Infection.
Novelli S; Lécuroux C; Avettand-Fenoel V; Seng R; Essat A; Morlat P; Viard JP; Rouzioux C; Meyer L; Goujard C
Clin Infect Dis; 2018 May; 66(10):1519-1527. PubMed ID: 29211834
[TBL] [Abstract][Full Text] [Related]
51. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
[TBL] [Abstract][Full Text] [Related]
52. Impact of polymorphisms in the HCP5 and HLA-C, and ZNRD1 genes on HIV viral load.
Thørner LW; Erikstrup C; Harritshøj LH; Larsen MH; Kronborg G; Pedersen C; Larsen CS; Pedersen G; Gerstoft J; Obel N; Ullum H
Infect Genet Evol; 2016 Jul; 41():185-190. PubMed ID: 27083073
[TBL] [Abstract][Full Text] [Related]
53. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.
Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC
N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775
[TBL] [Abstract][Full Text] [Related]
54. Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy.
Chaix ML; Seng R; Frange P; Tran L; Avettand-Fenoël V; Ghosn J; Reynes J; Yazdanpanah Y; Raffi F; Goujard C; Rouzioux C; Meyer L;
Clin Infect Dis; 2013 Mar; 56(6):880-7. PubMed ID: 23223603
[TBL] [Abstract][Full Text] [Related]
55. Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes.
Lima VD; Reuter A; Harrigan PR; Lourenço L; Chau W; Hull M; Mackenzie L; Guillemi S; Hogg RS; Barrios R; Montaner JS
AIDS; 2015 Sep; 29(14):1871-82. PubMed ID: 26165354
[TBL] [Abstract][Full Text] [Related]
56. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.
Hulgan T; Shepherd BE; Raffanti SP; Fusco JS; Beckerman R; Barkanic G; Sterling TR
J Infect Dis; 2007 Feb; 195(3):425-31. PubMed ID: 17205482
[TBL] [Abstract][Full Text] [Related]
57. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.
Parczewski M; Siwak E; Leszczyszyn-Pynka M; Cielniak I; Burkacka E; Pulik P; Witor A; Muller K; Zasik E; Grzeszczuk A; Jankowska M; Lemańska M; Olczak A; Grąbczewska E; Szymczak A; Gąsiorowski J; Szetela B; Bociąga-Jasik M; Skwara P; Witak-Jędra M; Jabłonowska E; Wójcik-Cichy K; Kamerys J; Janczarek M; Krankowska D; Mikuła T; Kozieł K; Bielec D; Stempkowska J; Kocbach A; Błudzin W; Horban A
J Int AIDS Soc; 2017 Jul; 20(1):21847. PubMed ID: 28715160
[TBL] [Abstract][Full Text] [Related]
58. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
Mocroft A; Staszewski S; Weber R; Gatell J; Rockstroh J; Gasiorowski J; Panos G; Monforte Ad; Rakhmanova A; Phillips AN; Lundgren JD;
Antivir Ther; 2007; 12(3):325-33. PubMed ID: 17591022
[TBL] [Abstract][Full Text] [Related]
59. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
[TBL] [Abstract][Full Text] [Related]
60. Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data.
Clements M; Law M; Pedersen C; Kaldor J;
HIV Med; 2003 Oct; 4(4):332-7. PubMed ID: 14525545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
